fda compounding semaglutide crackdown 2025 news issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of The FDA's Decision to Ban
Description
We want to see you succeed, which is why we take your whole body into account
If you need to mix the contents, gently roll the vial between your palms
Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy
The STEP 1 extension study showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within a year
Not as a failure of the first drug but as a logical progression as obesity medicine gives patients better and better options
Wen J, Nadora D, Bernstein E, et al
